MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

ReNeuron Group Plc Company Profile (LON:RENE)

Consensus Ratings for ReNeuron Group Plc (LON:RENE) (?)
Ratings Breakdown: 1 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: GBX 10

Analysts' Ratings History for ReNeuron Group Plc (LON:RENE)
Show:
DateFirmActionRatingPrice TargetActions
1/4/2016N+1 SingerReiterated RatingBuyGBX 10View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/30/2014 forward)
Earnings History for ReNeuron Group Plc (LON:RENE)
No earnings announcements for this company have been tracked by MarketBeat.com

Earnings Estimates for ReNeuron Group Plc (LON:RENE)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for ReNeuron Group Plc (LON:RENE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for ReNeuron Group Plc (LON:RENE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
2/17/2016Hunt,MichaelInsiderSell509,554GBX 3£15,286.62Tweet This Trade  Share This Trade on StockTwits
2/12/2016Hunt,MichaelInsiderSell594,637GBX 3£17,839.11Tweet This Trade  Share This Trade on StockTwits
2/11/2016Hunt,MichaelInsiderSell1,208,333GBX 3£36,249.99Tweet This Trade  Share This Trade on StockTwits
2/5/2016Hunt,MichaelInsiderSell1,035,533GBX 3£31,065.99Tweet This Trade  Share This Trade on StockTwits
2/2/2016Edward Berriman,JohnInsiderBuy318,476GBX 3£9,554.28Tweet This Trade  Share This Trade on StockTwits
1/29/2015Olav HellebøInsiderBuy322,778GBX 3.10£10,006.12Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for ReNeuron Group Plc (LON:RENE)
DateHeadline
06/29/16 08:52 AMReNeuron Group (LON:RENE) Broker Updates - Fiscal Standard
06/15/16 10:38 AMReNeuron completes recruitment for phase II stroke trial - Proactive Investors UK
06/14/16 10:53 AMReNeuron : Notification of Preliminary Results
06/14/16 04:29 AMPatient recruitment completed in Phase II stroke clinical trial - [at noodls] - Consolidated income statement 13 June 2016 AIM: RENE ReNeuron Group plc ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, ...
06/13/16 05:40 PMReNeuron : Patient recruitment completed in stroke trial
06/13/16 05:40 PMReNeuron completes recruitment for phase II stroke trial
06/13/16 09:03 AMFitbug catches cold as FTSE 100 Index drops - Proactive Investors UK
06/13/16 09:03 AMReNeuron completes recruitment for phase II stroke trial - Proactive Investors USA & Canada
06/13/16 02:19 AMPatient recruitment completed in stroke trial - [at noodls] - ReNeuron Group plc Patient recruitment completed in Phase II stroke clinical trial ReNeuron Group plc (the 'Company') (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, ...
06/09/16 09:04 AMReNeuron to tackle brain cancer with exosome candidate - Proactive Investors UK
06/09/16 02:29 AMPursues brain cancer with exosome platform - [at noodls] - AIM: RENE 9June 2016 ReNeuron Group plc ReNeuron to pursue brain cancer as first clinical target for exosome nanomedicine platform ReNeuron Group plc (the 'Company') (AIM: RENE), a UK-based global leader ...
06/09/16 02:29 AMReNeuron to pursue brain cancer as first clinical target for exosome nanomedicine platform - [at noodls] - Consolidated income statement AIM: RENE 9 June 2016 ReNeuron Group plc ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, ...
06/08/16 06:35 PMReNeuron making good progress in clinical trial, says CFO - Proactive Investors USA & Canada
06/08/16 09:06 AMReNeuron clinical trial making progress - Proactive Investors UK
06/08/16 03:28 AMRetinitis pigmentosa Phase I/II clinical trial update and Notice of US Key Opinion Leader event - [at noodls] - ReNeuron Group plc (the 'Company') (AIM: RENE), a leading UK-based stem cell therapy development company, is pleased to provide an update on progress with the ongoing US Phase I/II dose escalation study ...
06/08/16 02:18 AMRetinitis pigmentosa update & Notice of KOL event - [at noodls] - AIM: RENE 8 June 2016 ReNeuron Group plc Retinitis pigmentosa Phase I/II clinical trial update and Notice of US Key Opinion Leader event ReNeuron Group plc (the 'Company') (AIM: RENE), a leading UK-based ...
05/31/16 08:19 AMReNeuron Group (LON:RENE) Analyst Target Changes - Share Trading News - ReNeuron Group (LON:RENE) Analyst Target ChangesShare Trading NewsReNeuron Group Plc (ReNeuron), based in the United Kingdom, is engaged in clinical-stage stem cell company. It is engaged in the research, development and commercial exploitation of stem cell technologies for therapeutic and non-therapeutic ...and more »
05/26/16 10:46 AMReneuron Group (LON:RENE) Morning Trade Volumes - Share Trading News - Share Trading NewsReneuron Group (LON:RENE) Morning Trade VolumesShare Trading NewsReNeuron Group Plc (ReNeuron), based in the United Kingdom, is engaged in clinical-stage stem cell company. It is engaged in the research, development and commercial exploitation of stem cell technologies for therapeutic and non-therapeutic ...and more »
02/26/16 12:55 PMAnalyst Coverage Updates - ReNeuron Group (LON:RENE) - Risers & Fallers - Analyst Coverage Updates - ReNeuron Group (LON:RENE)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of ReNeuron Group (LON:RENE). The latest broker reports which are currently outstanding on Wednesday 24th of February state 2 analysts have a rating of “strong buy”, ...and more »
02/26/16 12:55 PMCan ReNeuron Group Plc's Tomorrow Be Different? The Stock Increases Again - Business Standard Tribune - Can ReNeuron Group Plc's Tomorrow Be Different? The Stock Increases AgainBusiness Standard TribuneThe stock of ReNeuron Group Plc (LON:RENE) is a huge mover today! The stock increased 4.36% or GBX 0.12 on February 25, hitting GBX 2.87. ReNeuron Group Plc (LON:RENE) has declined 49.56% since July 27, 2015 and is downtrending.and more »
02/07/16 01:40 PMFTSE Miners: Don't look a gift horse.... - Proactive Investors UK - FTSE Miners: Don't look a gift horse....Proactive Investors UKResurgent FTSE Miners are waving the wooden spoon this morning, giving up ground as traders who dared bottom-pick over the last 3 weeks sensibly book some handsome and very welcome 10-40% profits following a helpful combination of USD weakness ...
02/03/16 01:38 PMStill selling the bounce? - Proactive Investors UK - Still selling the bounce?Proactive Investors UKEquity markets mixed this morning, with a little oil price strength stemming earlier declines. Markets could be moving on past a string of arguably expected Oil Major earnings reports, while we note the potential for this to be mere consolidation ahead ...
02/03/16 01:38 PMNorthland Capital Partners View on the City TechFinancials, Quarto Group, Access Intelligence - Proactive Investors UK - Northland Capital Partners View on the City TechFinancials, Quarto Group, Access IntelligenceProactive Investors UKTechFinancials has entered into JV agreement in the B2C business segment, with the aim of increasing the company's B2C market share. TechFinancials has struck an agreement with IBID Holdings Limited (the Partner), a Hong Kong registered company ...and more »
02/03/16 01:38 PMNWF chief confident of meeting profit targets in 2016 - Proactive Investors UK - NWF chief confident of meeting profit targets in 2016Proactive Investors UKNWF Group (LON:NWF) is a 140 year old company focused on food, feed and fuel and chief executive Richard Whiting spoke to Proactive about its latest results. The firm's latest results showed pre-tax profit rose 4% to £2.6mln on slightly lower revenue ...and more »
02/03/16 01:38 PMKEFI Minerals pleased funding is progressing according to plans - Proactive Investors UK - KEFI Minerals pleased funding is progressing according to plansProactive Investors UKHarry Adams, KEFI Minerals's chairman (LON:KEFI), says funding is moving according to plans after the group selected two African banks to provide US$60 mln of debt finance for the development of the Tulu Kapi gold project in Ethiopia. Adams says the ...and more »
02/01/16 01:36 PMBeaufort Securities Breakfast Alert: Ariana Resources, Ferrum Crescent, Keras and others - Proactive Investors UK - Beaufort Securities Breakfast Alert: Ariana Resources, Ferrum Crescent, Keras and othersProactive Investors UKAny group that can position itself to secure online revenues from the PRC's twin obsessions, namely Lottery and Poker, while monetizing an increasingly liberated market, will add considerable value. Beaufort considers the shares offer value up to 5p ...and more »
02/01/16 01:36 PMStrategic Minerals boss says project switch creates better return for shareholders - Proactive Investors UK - Strategic Minerals boss says project switch creates better return for shareholdersProactive Investors UKJohn Peters, executive chairman, said: “This opportunity came along in a sector that we believe has good medium and long-term prospects.” In a separate statement, the group said it had stopped activity on its Tatu coal project in New Zealand to ...and more »
02/01/16 01:36 PMReNeuron Gets Notice Of Grant For US Cell Cryopreservation P - London South East (registration) (blog) - BioPharma-Reporter.comReNeuron Gets Notice Of Grant For US Cell Cryopreservation PLondon South East (registration) (blog)"The US Notice of Allowance for our cell cryopreservation technology is an important further addition to ReNeuron's extensive patent estate. We have invested heavily in patents over the years, an investment that we believe will provide significant ...ReNeuron Receives Notice of Grant of Key US Patent on its Cell Cryopreservation Technologyag-IP-news Agencyall 5 news articles »
02/01/16 02:19 AMNotice of Grant of Key US Patent - [at noodls] - RNS Number : 5491N ReNeuron Group plc 01 February 2016 1 February 2016 AIM: RENE ReNeuron Group plc ReNeuron receives notice of grant of key US patent on its cell cryopreservation... This is an abstract ...
01/30/16 01:14 PMEverything's rosy, n'est ce pas? - Proactive Investors UK - Everything's rosy, n'est ce pas?Proactive Investors UKEquity markets still on the up, digesting the Fed's January policy update as a positive with the tough start to January and market volatility a potential negative for the US economy, likely keeping the US central bank from hiking rates quickly in 2016 ...and more »
01/29/16 01:33 PMNorthland Capital Partners View on the City - Quarto Group - Proactive Investors UK - Northland Capital Partners View on the City - Quarto GroupProactive Investors UKStrong performance in Quarto's core publishing businesses in the final quarter means it should exceed expectations for FY15. Quarto's market-leading presence in the adult colouring book category, particularly in North America, and the better than ...and more »
01/29/16 01:33 PMGlencore-Leader of the pack - Proactive Investors UK - Glencore-Leader of the packProactive Investors UKGlencore (LON:GLEN) shares are leading the FTSE Mining sector higher this morning, maintaining their recovery trend from mid-month lows. This despite some indirect USD strength from the Bank of Japan's (BoJ) decision to join major peers like the ECB ...
01/29/16 01:33 PMLearning Tech CEO expects more acquisitions after recent deals - Proactive Investors UK - Learning Tech CEO expects more acquisitions after recent dealsProactive Investors UKLearning Technologies Group (LON:LTG) chief executive Jonathan Satchell told Proactive he could “pretty much guarantee” there will be more acquisitions to come, after the firm spent US$30mln on Friday. The firm is to acquire Rustici Software LLC, ...and more »
01/29/16 01:33 PMPCG Entertainment chief not fazed by potential Chinese slowdown - Proactive Investors UK - PCG Entertainment chief not fazed by potential Chinese slowdownProactive Investors UK“China is looking more and more to consumer spending to generate growth in the country and that's good for us,” he said. He was speaking as the Asia-Pacific focused online gaming and media group said operating profits for the fourth quarter almost ...and more »
01/27/16 12:54 PMAnalysts Consensus For ReNeuron Group (LON:RENE) - Risers & Fallers - Analysts Consensus For ReNeuron Group (LON:RENE)Risers & FallersReNeuron Group Plc (ReNeuron), based in the United Kingdom, is engaged in clinical-stage stem cell company. It is engaged in the research, development and commercial exploitation of stem cell technologies for therapeutic and non-therapeutic ...and more »
01/26/16 01:27 PMInterim Management Statement - Yahoo Finance UK - Interim Management StatementYahoo Finance UKOther stocks that made a significant contribution included Learning Technologies Group (+28.3%, +0.41 pence per share), K3 Business Technology Group (+21.8%, +0.41 pence per share) and Idox (+25.9%, +0.39 pence per share). ... On 1 December 2015, the ...
01/12/16 02:10 AMPre-clinical data relating to exosome platform - [at noodls] - RNS Number : 5242L ReNeuron Group plc 12 January 2016 12 January 2016 AIM: RENE ReNeuron Group plc Publication of pre-clinical data relating to ReNeuron's exosome nanomedicine platform Data support the... ...
01/11/16 04:47 AMReNeuron wins major UK grant to advance its exosome nanomedicine platform - [at noodls] - Consolidated income statement 11 January 2016 AIM: RENE ReNeuron Group plc Guildford, UK, 11 January 2016: ReNeuron Group plc (the "Company") (AIM: RENE), a leading UK-based stem cell therapy ...
01/11/16 02:37 AMWins UK grant to advance its exosome platform - [at noodls] - RNS Number : 3704L ReNeuron Group plc 11 January 2016 11 January 2016 AIM: RENE ReNeuron Group plc ReNeuron wins major UK grant to advance its exosome nanomedicine platform Guildford, UK, 11 January... ...
12/17/15 02:11 AMReNeuron establishes Scientific Advisory Board - [at noodls] - Guildford, UK, 17 December 2015:ReNeuron Group plc (the 'Company') (AIM: RENE), a leading UK-based stem cell therapy development company, is pleased to announce that it has held the inaugural meeting of ...
12/09/15 08:07 AMAre Diageo plc, ReNeuron Group Plc & Persimmon plc On The Cusp Of Huge Returns? -
11/02/15 02:26 AMCEO presents at the 2015 Stem Cell meeting on the MESA - [at noodls] - CEO presents at the 2015 Stem Cell meeting on the MESA
10/02/15 10:00 AMDirectors’ Interest in Shares and Share Options - [at noodls] - RNS Number : 1172B ReNeuron Group plc 02 October 2015 2 October 2015 AIM: RENE ReNeuron Group plc ('ReNeuron' or 'the Company') Directors' Interest in Shares and Share Options Guildford, UK, 2 October ...
09/28/15 07:07 AMBlock Admission and Total Voting Rights - [at noodls] - RNS Number : 3995A ReNeuron Group plc 28 September 2015 28 September 2015 AIM: RENE ReNeuron Group plc ('ReNeuron' or 'the Company') Guildford, UK, 28 September 2015: ReNeuron Group plc (AIM: RENE)... ...
About ReNeuron Group Plc

ReNeuron Group Plc logoReNeuron Group Plc (ReNeuron), based in the United Kingdom, is engaged in clinical-stage stem cell company. It is engaged in the research, development and commercial exploitation of stem cell technologies for therapeutic and non-therapeutic applications. It develops cell-based therapies for disease conditions where the cells can be readily administered off-the-shelf to any eligible patient without the need for additional drug treatments. Its lead therapeutic candidate is its ReN001 stem cell therapy for the treatment of patients left disabled by the effects of a stroke. Its ReNcell products are used in academic and commercial sectors. Its ReN009 stem cell candidate is for the treatment of critical limb ischaemia, a side effect of diabetes. This treatment is in early-stage clinical development. Its ReN003 stem cell candidate is for the treatment of retina pigmentosa, a blindness-causing disease of the retina. This treatment is in late pre-clinical development.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: LON
  • Symbol: RENE
  • CUSIP:
Key Metrics:
  • Previous Close: $0.04
  • 50 Day Moving Average: $3.262
  • 200 Day Moving Average: $3.119
  • P/E Ratio: N/A
  • P/E Growth: 0.000
  • Market Cap: $90.98B
  • Current Quarter EPS Consensus Estimate: $-0.550 EPS
Additional Links:

            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha